Leo Pharma IPO plans stalled by market volatility: Bloomberg

dominoes, stop, stall, halt, end, red
Leo Pharma is among several companies that have stalled IPO plans in the wake of market volatility caused by geopolitical uncertainty and inflation pressures. (klenger/iStock/Getty Images Plus)

Leo Pharma appears to be second guessing its plans for a 2026 initial public offering.  

CEO Christophe Bourdon said that an IPO remains a “natural and viable option” for the Danish drugmaker, which specializes in dermatology treatments, but that the company's shareholders have opted to delay that strategy out past this year, due to volatility in the global markets, Bloomberg first reported following an interview with the chief executive. 

The news comes one week after Danish paper Berlingske reported an anonymous tip that Leo was weighing an IPO postponement. Bourdon did not offer an alternative timeline for the public listing in his conversation with Bloomberg. 

Leo's decision to delay its plan lands amid an already muted European IPO scene in 2026. 

European IPO volume between September and October landed at around 2 billion euros, down more than 70% from 8 billion euros over the same period in 2025, according to recent analyst reports. And the U.S. tally from November has been similarly slim. Meanwhile, of the 30 IPOs completed in Europe in 2026 so far, many are trading below their offering price. 

Globally, investors continue to be rattled by inflation, rising interest rates and geopolitical tensions. 

"The timing of the IPO lies ​in the hands of the shareholders and both shareholders have assessed that current market conditions do not support a listing," Bourdon said, referencing the Leo Foundation, which own an 80% stake in Leo Pharma, and Nordic Capital, which acquired the remaining 20% in 2021. 

“LEO Pharma is in a strong financial and strategic position, with attractive growth and value-creation opportunities," Leo Foundation CEO Peter Haahr told Fierce in a statement. "We continue to see a public listing as a natural evolution and a beneficial ownership structure for the company. We are not bound by a timetable and will pursue a listing when we consider the timing right for the company and its shareholders.”

The pharma is one of Denmark’s oldest, founded in 1908. Its ambitions around an IPO picked up in 2021 when Nordic Capital became the minority shareholder and Leo set plans for an exit within four to five years. 

The offering began to take shape earlier this year, when Leo began courting prospective investors and enlisted seven banks to help run its potential Copenhagen listing. At the time, Bourdon told Bloomberg a 2026 IPO was a “realistic possibility” and that Leo was positioning itself to “be ready when shareholders decide to push the button.”

Bourdon took the helm in 2022, shortly after Leo had embarked on a restructuring initiative the previous year. 

During his tenure, the CEO has continued to work to reduce costs, trimming the company’s headcount from around 6,000 to 4,000 through early 2024. Bourdon also pivoted the company toward external innovation as opposed to it’s long-time investments in internal R&D. Former Boehringer Ingelheim rare disease drug Spevigo represents at least one notable purchase for Leo under Bourdon’s leadership. 

The overhaul appears to be paying off, too. On Monday, Leo reported 11% revenue growth for the third quarter, putting the company on track to hit its 9% to 11% growth target for the year.

Amid the uncertainty around the timing of Leo’s future financial structure, Bourdon told Bloomberg he’s staying focused “on what I can control best, which is the performance of the company, delivering in line with our strategic ambition.”